{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:38:52Z","timestamp":1771522732909,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004147","name":"Tsinghua University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115914","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:19:21Z","timestamp":1763828361000},"page":"115914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Jubang Huashi Yin and its active component cynaroside alleviate excessive inflammation in COVID-19 by inhibiting IKK\u03b2 activity"],"prefix":"10.1016","volume":"168","author":[{"given":"Wenting","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liansheng","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115914_bb0005","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115914_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115914_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115914_bb0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2025.115914_bb0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2025.115914_bb0030","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/imr.12977","article-title":"COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts","volume":"302","author":"John","year":"2021","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115914_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/thoraxjnl-2021-217561","article-title":"Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19","volume":"77","author":"Bridges","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.intimp.2025.115914_bb0045","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3390\/ijms22052566","article-title":"The history and mystery of alveolar epithelial type II cells: focus on their physiologic and pathologic role in lung","volume":"22","author":"Ruaro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115914_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00188-21","article-title":"SARS-CoV-2 infection and lung regeneration","volume":"35","author":"Zhao","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2025.115914_bb0055","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","author":"Self","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2025.115914_bb0065","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115914_bb0070","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Peter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0085","doi-asserted-by":"crossref","first-page":"2002808","DOI":"10.1183\/13993003.02808-2020","article-title":"Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial","volume":"56","author":"Edalatifard","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115914_bb0090","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2020.04.002","article-title":"Clinical features of COVID-19-related liver functional abnormality","volume":"18","author":"Fan","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.115914_bb0095","article-title":"SARS-CoV-2 omicron variants reduce antibody neutralization and acquire usage of mouse ACE2","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115914_bb0100","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1002\/jmv.28066","article-title":"Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 omicron variant: a systematic review and analysis","volume":"94","author":"Yu","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2025.115914_bb0105","first-page":"S35","article-title":"Developing influenza treatments using traditional Chinese medicine","volume":"347","author":"Yang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115914_bb0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7326\/0003-4819-155-4-201108160-00005","article-title":"Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial","volume":"155","author":"Wang","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107843","article-title":"Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms","volume":"225","author":"Huang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.115914_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.928468","article-title":"Jinhua Qinggan granules for non-hospitalized COVID-19 patients: a double-blind, placebo-controlled, and randomized controlled trial","volume":"9","author":"Shah","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153242","article-title":"Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial","volume":"85","author":"Hu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.115914_bb0130","series-title":"Treatment Effects of Xuebijing Injection in Severe Septic Patients with Disseminated Intravascular Coagulation","author":"Yin","year":"2014"},{"key":"10.1016\/j.intimp.2025.115914_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153531","article-title":"Association between use of Qingfei Paidu tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study","volume":"85","author":"Zhang","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.115914_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.imr.2020.100489","article-title":"Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial","volume":"9","author":"Xiong","year":"2020","journal-title":"Integr. Med. Res."},{"key":"10.1016\/j.intimp.2025.115914_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153671","article-title":"Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial","volume":"91","author":"Liu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.115914_bb0150","first-page":"577","article-title":"Evaluation of the immunomodulatory effects of anti-COVID-19 TCM formulae by multiple virus-related pathways","volume":"6","author":"Qiao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115914_bb0155","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1073\/pnas.1200305109","article-title":"Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2025.115914_bb0160","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0165","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115914_bb0170","first-page":"103","article-title":"The development of Chinese herbal formulae for non-severe COVID-19 based on artificial intelligence technology and investigation of its action mechanisms","volume":"65","author":"Huang","year":"2024","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0175","first-page":"217","article-title":"The exploration of a new approach for developing innovative Chinese herbal formulae by combining targeted transcriptome, expert experience and artificial intelligence: taking the development of antichronic heart failure innovative formula as an example","volume":"64","author":"Qiao","year":"2023","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0180","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115914_bb0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jare.2021.11.012","article-title":"Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection","volume":"36","author":"Yi","year":"2022","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.intimp.2025.115914_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153333","article-title":"Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV spike pseudotyped virus","volume":"79","author":"Wang","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.115914_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-021-00531-5","article-title":"Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115914_bb0200","doi-asserted-by":"crossref","first-page":"22758","DOI":"10.1074\/jbc.M113.482596","article-title":"Crystal structure of a human I\u03baB kinase \u03b2 asymmetric dimer","volume":"288","author":"Liu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115914_bb0205","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/ijms17122099","article-title":"Discovery of anti-hypertensive oligopeptides from adlay based on in silico proteolysis and virtual screening","volume":"17","author":"Qiao","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115914_bb0210","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41422-021-00495-9","article-title":"SARS-CoV-2 spike protein interacts with and activates TLR4","volume":"31","author":"Zhao","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2025.115914_bb0215","article-title":"Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115914_bb0220","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1142\/S0192415X20500421","article-title":"Chrysanthemum indicum L.: a comprehensive review of its botany, phytochemistry and pharmacology","volume":"48","author":"Shao","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.intimp.2025.115914_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.111917","article-title":"Chrysanthemum indicum extract inhibits NLRP3 and AIM2 inflammasome activation via regulating ASC phosphorylation","volume":"239","author":"Yu","year":"2019","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.intimp.2025.115914_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/246407","article-title":"The protective effects of the supercritical-carbon dioxide fluid extract of Chrysanthemum indicum against lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathway","volume":"2014","author":"Wu","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2025.115914_bb0235","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.fct.2012.02.034","article-title":"The extract of Chrysanthemum indicum Linne inhibits EBV LMP1-induced NF-\u03baB activation and the viability of EBV-transformed lymphoblastoid cell lines","volume":"50","author":"Kim","year":"2012","journal-title":"Food Chem. Toxicol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:58:35Z","timestamp":1771520315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925019022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"alternative-id":["S1567576925019022"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115914","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Jubang Huashi Yin and its active component cynaroside alleviate excessive inflammation in COVID-19 by inhibiting IKK\u03b2 activity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115914"}}